Karakteristik Pengobatan dan Biaya Medis Langsung Kanker Payudara pada Kemoterapi Rawat Jalan di RSUD Dr. M. Yunus Tahun 2023

https://doi.org/10.22146/farmaseutik.v21i4.103487

Dika Aryan Utami(1*), Tri Murti Andayani(2), Dwi Endarti(3)

(1) Magister Manajemen Farmasi, Farmasi, Universitas Gadjah Mad
(2) Departemen Farmakologi dan Farmasi Klinik, Farmasi, Universitas Gadjah Mada
(3) Departemen Farmasetika, Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Kanker payudara merupakan jenis kanker dengan prevalensi tertinggi di Indonesia dan secara global, yang memerlukan analisis biaya pengobatan untuk mencapai efektivitas terapi. Penelitian ini bertujuan untuk menganalisis karakteristik pengobatan kanker payudara pada pelayanan kemoterapi rawat jalan di RSUD Dr. M. Yunus selama periode 1 Januari hingga 31 Desember 2023 dan merupakan penelitian deskriptif dengan desain penelitian cross-sectional. Data yang digunakan dalam penelitian ini diambil dari SIM RS dan rekam medis pasien, yang kemudian dianalisis menggunakan perangkat lunak RStudio. Hasil penelitian menunjukkan bahwa terdapat 2.268 pelayanan kemoterapi rawat jalan untuk 386 pasien, mayoritas berusia 40–44 tahun. Pengobatan diberikan melalui tiga rute: intravena (IV), oral (PO), dan kombinasi (injeksi dan oral), dengan total 31 regimen pengobatan. Total biaya medis langsung mencapai Rp 5.719.995.986, dengan rata-rata biaya per pasien sebesar Rp 2.522.044. Rute intravena (IV) paling sering digunakan (49,87%), sementara regimen EC-T (Epirubicin, Cyclophosphamide, dan Docetaxel) paling banyak diberikan (32,80%). Regimen Paclitaxel-Trastuzumab memiliki biaya medis langsung tertinggi, yaitu Rp 9.002.322. Penelitian ini memberikan wawasan tentang karakteristik pengobatan kanker payudara di RSUD Dr. M. Yunus dan diharapkan dapat menjadi dasar perancangan kebijakan berbasis data untuk meningkatkan efektivitas pelayanan kesehatan.


Keywords


Kemoterapi; Kanker Payudara; Pelayanan Rawat Jalan; RStudio



References

Abd. Mirsyad, Azis Beru Gani, Karim, M., Raeny Purnamasari, Karsa, N. S., Andi Husni Tanra, & Julia. (2022). Hubungan Usia Pasien Dengan Tingkat Stadium Kanker Payudara Di RS Ibnu Sina Makassar 2018. Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran, 2(2), 109–115. https://doi.org/10.33096/fmj.v2i2.48

Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., Leheurteur, M., Domont, J., Gutierrez, M., Curé, H., Ferrero, J.-M., & Labbe-Devilliers, C. (2013). Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. The Lancet Oncology, 14(1), 64–71. https://doi.org/10.1016/S1470-2045(12)70432-1

Benjamin, L., Buthion, V., Iskedjian, M., Farah, B., Rioufol, C., & Vidal-Trécan, G. (2013). Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of Medical Economics, 16(1), 96–107. https://doi.org/10.3111/13696998.2012.729549

DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583

Jalal, H., Pechlivanoglou, P., Krijkamp, E., Alarid-Escudero, F., Enns, E., & Hunink, M. G. M. (2017). An Overview of R in Health Decision Sciences. Medical Decision Making, 37(7), 735–746. https://doi.org/10.1177/0272989X16686559

Kemenkes RI. (2019). Profil Kesehatan Indonesia Tahun 2019. Kementerian Kesehatan Republik Indonesia.

Lairson, D. R., Parikh, R. C., Cormier, J. N., Chan, W., & Du, X. L. (2015). Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value in Health, 18(8), 1070–1078. https://doi.org/10.1016/j.jval.2015.08.008

Madden, R., Kosari, S., Peterson, G. M., Bagheri, N., & Thomas, J. (2018). Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review. Int. Journal of Clinical Pharmacology and Therapeutics, 56(02), 72–80. https://doi.org/10.5414/CP203123

Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians, 66(4), 271–289. https://doi.org/10.3322/caac.21349

Muhammet Fatih Ak. (2020). A Comparative Analysis of Breast Cancer Detection and Diagnosis Using Data Visualization and Machine Learning Applications. Healthcare, 8(2), 111. https://doi.org/10.3390/healthcare8020111

Nitz, U. A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., … Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Annals of Oncology, 28(11), 2768–2772. https://doi.org/10.1093/annonc/mdx494

Schramm, A., De Gregorio, N., Widschwendter, P., Fink, V., & Huober, J. (2015). Targeted Therapies in HER2-Positive Breast Cancer—A Systematic Review. Breast Care, 10(3), 173–178. https://doi.org/10.1159/000431029

Sharma, Wojtynek, J., Fox, K, Cooper, Chelsea, & Dokubo, I. (2021). Cost of home vs clinic administration of paclitaxel in metastatic breast cancer. The American Journal of Managed Care, 27(Spec. No. 2), SP46–SP50. https://doi.org/10.37765/ajmc.2021.88563

Sohi, G. K., Levy, J., Delibasic, V., Davis, L., Mahar, A., Amirazodi, E., Earle, C., Hallet, J., Hammad, A., Mittmann, N., & Coburn, N. (2020). The cost of chemotherapy administration: A systematic review and meta-analysis. Journal of Clinical Oncology, 38(4_suppl), 810–810. https://doi.org/10.1200/JCO.2020.38.4_suppl.810

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Vermunt, M. A. C., Bergman, A. M., Van Der Putten, E., & Beijnen, J. H. (2021). The Intravenous to Oral Switch of Taxanes: Strategies and Current Clinical Developments. Future Oncology, 17(11), 1379–1399. https://doi.org/10.2217/fon-2020-0876

Wickham, H. (2016). Data Analysis. Dalam H. Wickham, Ggplot2 (hlm. 189–201). Springer International Publishing. https://doi.org/10.1007/978-3-319-24277-4_9



DOI: https://doi.org/10.22146/farmaseutik.v21i4.103487

Article Metrics

Abstract views : 50

Refbacks

  • There are currently no refbacks.


©Majalah Farmaseutik
 ISSN 2406-9086
Faculty of Pharmacy
Universitas Gadjah Mada
 
 
web analytics 

Creative Commons Licence 
 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License